v3.25.2
Segment Information
6 Months Ended
Jun. 30, 2025
Segment Reporting [Abstract]  
Segment Information

3. Segment Information

 

The Company’s chief operating decision maker (“CODM”) has been identified as the Company’s Chief Executive Officer (“CEO”). The Company’s CODM evaluates performance and makes operating decisions about allocating resources based on financial data presented on a consolidated basis. Because the CODM evaluates financial performance on a consolidated basis, the Company has determined that it currently has a single operating segment which is comprised of the consolidated financial results of the Company.

 

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in research and development costs for the three months and six months ended June 30, 2025 and 2024.

 

   2025   2024   2025   2024 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2025   2024   2025   2024 
                 
Clinical and related oversight costs  $11,601   $97,947   $27,470   $107,977 
Preclinical research focused on development of additional novel anti-cancer compounds   27,592    104,829    70,362    209,309 
Compound maintenance   20,265    5,976    53,083    9,870 
Regulatory service costs   1,190    1,956    1,190    2,616 
Total research and development costs  $60,648   $210,708   $152,105   $329,772 

 

The following table presents a summary of research and development costs for the three months and six months ended June 30, 2025 and 2024 based on the respective geographical regions where such costs were incurred.

 

   2025   2024   2025   2024 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2025   2024   2025   2024 
                 
United States  $41,928   $114,345   $100,499   $148,928 
Spain   18,720    29,244    51,606    44,478 
China               2,282 
Netherlands       67,119        134,084 
Total research and development costs  $60,648   $210,708   $152,105   $329,772 

 

The following table presents the significant segment expenses (10% or greater) and other segment items regularly reviewed by the Company’s CODM and included in general and administrative costs for the three months and six months ended June 30, 2025 and 2024.

 

   2025   2024   2025   2024 
   Three Months Ended   Six Months Ended 
   June 30,   June 30, 
   2025   2024   2025   2024 
                 
Compensation to related parties:                    
Cash-based  $123,285   $175,663   $232,016   $390,398 
Stock-based   267,999    130,691    367,737    233,618 
Patent and licensing legal and filing fees and costs   17,303    63,612    73,386    146,823 
Other consulting and professional fees   176,551    191,529    381,867    363,972 
Insurance expense   64,277    126,873    128,553    253,727 
Other costs and expenses, net   64,746    110,080    146,085    257,725 
Total general and administrative costs  $714,161   $798,448   $1,329,644   $1,646,263 

 

The following table presents the Company’s total assets by segment at June 30, 2025 and December 31, 2024.

 

  

June 30,

2025

   December 31,
2024
 
         
Research and development assets  $20,041   $39,298 
Corporate assets (primarily cash)   1,168,537    1,106,205 
Total assets  $1,188,578   $1,145,503